

WEST Search History

[Hide Items](#) [Restore](#) [Clear](#) [Cancel](#)


DATE: Monday, December 05, 2005

<u>Hide?</u>	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>			
■	L6	L5 and cancer	37
■	L5	L2 and L4	39
■	L4	L1 and pyrazine	278
■	L3	L1 and benzimazole	0
■	L2	L1 and quinolone	261
■	L1	tyrosine kinase inhibitor	4155

END OF SEARCH HISTORY

10/106 238

L6 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 405169-16-6 REGISTRY
CN 2(1H)-Quinolinone, 4-amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one
FS 3D CONCORD
MF C21 H21 F N6 O
CI COM
SR CA
LC STN Files: CA, CAPIUS, CASREACT, IMSDRUGNEWS, IMSRESEARCH, PROUSDDR,
SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);
PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: ANST (Analytical
study); BIOL (Biological study); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT